Hypertensive serum extracellular vesicle protein markers and their applications
By detecting SPARC levels in serum extracellular vesicles, a biomarker for diagnosing hypertension is provided, solving the problem of difficult to effectively diagnose early stages of hypertension in the prior art, and improving the sensitivity and specificity of the diagnosis , help individualize treatment plans.
Patent Information
- Application Number
- CN202111122344.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-09-24
AI Technical Summary
The prior art is difficult to effectively diagnose and evaluate the early stages of hypertension, especially at the individual level, to provide accurate diagnosis and treatment options for cardiovascular diseases, and lack affordable, minimally invasive or non-invasive monitoring tools.
By detecting the SPARC level in serum extracellular vesicles, using Luminex quantitative detection, ELISA reagent, mass spectrometry, flow cytometry or western blot, kits and detection systems are provided to diagnose or predict hypertension and related methods. Disease risk.
Improve the sensitivity and specificity of hypertension diagnosis, can assist in the effectiveness of treatment plans, provide disease grading, screening and monitoring, help judge the risk of hypertension and related diseases, and combine blood pressure monitoring to more accurately The patient's pathological status was found.
Smart Images

Figure CN113832223B_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of medical detection, especially hypertension detection. Specifically, the present application provides the use of SPARC in extracellular vesicles, especially serum extracellular vesicles, as a marker for hypertension or hypertension-related diseases; the present application also provides corresponding kits, detection methods and detection systems. Background Art
[0002] Hypertension is a major risk factor for cardiovascular disease and the leading cause of death in China [1]. A national survey shows that approximately 240 million people aged 18 and over in my country suffer from hypertension [2]. At present, there is still a lack of research on the modifiable risk factors for hypertension in my country, but it is certain that improving the symptoms of hypertension and related diseases will greatly reduce the disability and mortality rates.
[0003] Blood pressure (BP) control mechanisms, such as cardiac output, peripheral vascular resistance, and circulating blood volume, lead to a variety of hypertension phenotypes. Each mechanism may increase BP in hypertensive patients to varying degrees, and it is important to choose the most appropriate treatment for each patient. The pathogenesis of hypertension involves the renin-angiotensin-aldosterone system [3], vascular smooth muscle [4] and endothelial dysfunction [5], as well as impaired platelet function [6] and antidiuretic hormone [3]. However, in most cases, the pathogenesis of hypertension remains unclear. For example, endothelial dysfunction is not only a driving factor for hypertension, but also leads to further deterioration of hypertension [7]. Therefore, it is of great clinical significance to explore affordable, minimally invasive or non-invasive diagnostic tools to assist BP monitoring, assess the stage of hypertension progression, and establish early evaluation indicators of hypertension, such as the initial stage of endothelial cell or smooth muscle damage, which will help clinicians to accurately diagnose and treat cardiovascular diseases. Blood is the most commonly used source of clinical liquid biopsy samples, and monitoring the protein components of serum or plasma has also become an important means to evaluate disease susceptibility, disease presence, and disease progression. There are many serum / plasma proteins that are widely tested as disease markers in clinical diagnosis. Currently, there are some reports on comparative blood sample studies and biomarker identification in hypertensive and control populations using serum. For example, epidemiological data show that plasma adiponectin levels are a biomarker and possible mediator of the development of obesity-related hypertension [8].
[0004] Extracellular vesicles (EVs) are a potential source of biomarkers for hypertension. EVs are small nano-sized vesicles that can be secreted by almost all cells and are present in various body fluids [9]. Because EVs carry proteins, RNA, and lipids, they are also called effectors and bridges for intercellular communication. The contents of EVs can also reflect the state of the parent cell. Secretory cells have targeted, precise regulation and high selectivity for the contents of EVs. Under different pathological and physiological conditions, cells secrete EVs containing specific contents into the extracellular environment (blood, urine, saliva, prostatic fluid, amniotic fluid, and pleural effusion, etc.)
[10] , acting on surrounding cells in a paracrine manner or distributed systemically through body fluids
[11] . Therefore, EVs can serve as a new source of biomarkers to optimize the precise diagnosis of clinically relevant hypertension, determine early end-organ damage, and identify new mechanisms of hypertension, thereby guiding and optimizing the clinical treatment of hypertension. The molecular markers of hypertension that have been reported so far are mainly proteins, metabolic small molecules, miRNA and other markers derived from liquid biopsy samples (including urine, blood, and saliva) of patients with hypertension. Compared with these markers, using the contents of EVs as diagnostic biomarkers has obvious advantages: (1) EVs contain tissue-, cell- or disease-specific proteins and nucleic acids; (2) The lipid bilayer provides protection for RNA, DNA and proteins in extracellular vesicles from the effects of nucleases and proteases in the extracellular environment; (3) The relative hardness of EVs makes it possible to use a wide range of methods to separate and enrich them from a range of body fluids (i.e., plasma, serum, urine, saliva, semen, milk, water and cerebrospinal fluid). These advantages of EVs make them more prominent and promising as a source of biomarkers. Since January 21, 2016, the first extracellular vesicle diagnostic company (Exosome Diagnostics, Inc.) was established and launched ExoDx. TM Since diagnostic kits represented by Lung (ALK) were used in clinical diagnosis, a number of extracellular vesicle-based diagnostic companies have been established both domestically and internationally, dedicated to the research of disease biomarkers of extracellular vesicles and the development of related products.
[0005] SPARC, also known as BM-40 or osteonectin, is a 32KD cellular glycoprotein that regulates the interaction between cells and the extracellular matrix by regulating cell adhesion, proliferation and matrix deposition
[12] . SPARC is highly expressed in tissues that undergo morphogenesis, remodeling and repair
[13] . The activity of platelet-derived growth factor, vascular endothelial growth factor and insulin-like growth factor is negatively regulated by SPARC
[14] . In patients with coronary artery disease, SPARC expression is elevated in adipose tissue and plasma. SPARC also mediates pathological mechanisms associated with diabetes and obesity. For example, renal biopsy results in rodent models of diabetic nephropathy
[15] and patients with diabetes and fibrotic renal damage
[16] showed significantly elevated SPARC expression; in addition, researchers detected SPARC levels in human adipose tissue and found that its expression was dominant in subcutaneous fat and that SPARC expression was also affected by fat content, leptin, blood glucose and insulin levels
[17] . The expression of SPARC mRNA in obese people is higher than that in non-obese people. SPARC can also inhibit adipogenesis through the Wnt / catenin signaling pathway
[18] . Clinical studies on SPARC are mainly focused on diabetes and its complications. There are very limited studies on SPARC in essential hypertension. The only few basic studies have shown that the damage to the kidneys caused by angiotensin II-induced hypertension is improved in SPARC knockout mice
[19] . Increased SPARC expression also contributes to the post-synthesis processing of collagen in pressure-overloaded hearts and increases diastolic stiffness
[20] . However, clinical studies on the correlation between SPARC levels in extracellular vesicles and systemic hypertension have not been reported. Summary of the invention
[0006] To further investigate the correlation between SPARC levels and systemic hypertension, we used Luminex quantitative detection to compare the differences in serum EV proteins between hypertensive and non-hypertensive patients. We identified that the expression of serum extracellular vesicle protein secreted protein acidic and rich in cysteine (SPARC) was increased in serum extracellular vesicles of hypertensive patients, and the changes in content were statistically significant compared with non-hypertensive controls.
[0007] On the one hand, the present application provides the use of a reagent for detecting the SPARC content in extracellular vesicles in the preparation of a kit for diagnosing hypertension or predicting the risk of hypertension and related diseases.
[0008] Furthermore, the reagent for detecting the SPARC content in extracellular vesicles includes an extracellular vesicle extraction reagent.
[0009] Furthermore, the reagent for detecting the SPARC content in extracellular vesicles includes a reagent for measuring the SPARC content in extracellular vesicles or measuring the SPARC mRNA level in extracellular vesicles.
[0010] Furthermore, the reagent for measuring the SPARC content in extracellular vesicles is Luminex reagent, ELISA reagent, mass spectrometry reagent, flow cytometry reagent or western blot reagent; preferably Detection reagents.
[0011] On the other hand, the present application provides the use of SPARC in extracellular vesicles as a marker for hypertension or the risk of hypertension and related diseases.
[0012] On the other hand, the present application provides a non-diagnostic method for diagnosing hypertension or predicting the risk of hypertension and related diseases, characterized in that the method includes the step of detecting the SPARC content in extracellular vesicles.
[0013] Furthermore, the step of detecting the SPARC content in extracellular vesicles includes an extracellular vesicle extraction step, and a step of measuring the SPARC content in serum extracellular vesicles or measuring the SPARC mRNA level in extracellular vesicles.
[0014] Further, the detection of SPARC content in extracellular vesicles uses Method, ELISA, mass spectrometry, flow cytometry or western blot; preferably Law.
[0015] Furthermore, when the SPARC content in the extracellular vesicles in the method is higher than 19.428 ng / mL, the sample subject is considered to have hypertension or a high risk of hypertension and related diseases.
[0016] Furthermore, the extracellular vesicles are extracellular vesicles in serum.
[0017] Furthermore, the hypertension is primary hypertension.
[0018] Furthermore, the hypertension-related diseases include diabetes, obesity, cardiovascular disease, and cerebral hemorrhage.
[0019] On the other hand, the present application provides a system for executing the above method, wherein the system includes an ELISA detection instrument, a Luminex liquid chip protein analysis platform instrument, a flow cytometer, a mass spectrometer or a western blot detection device.
[0020] The serum extracellular vesicle extraction reagents in the present application can be reagents used in serum extracellular vesicle extraction methods known in the art or under research, including but not limited to ultracentrifugation, density gradient centrifugation, precipitation, molecular exclusion, microfluidics, immunoadsorption and the like. These methods and the reagents available therein are well known to those skilled in the art or can be determined by reference to known textbooks or literature.
[0021] The reagents for measuring the SPARC content in serum extracellular vesicles in the present application can be reagents for measuring the SPARC content in serum extracellular vesicles known or under research in the art, including but not limited to Reagents, ELISA reagents, mass spectrometry reagents, flow cytometry reagents, western blot reagents, etc. These methods and reagents that can be used therein are well known to those skilled in the art or can be determined by referring to known textbooks or literature.
[0022] In the present application, the reagents for measuring the level of SPARC mRNA in extracellular vesicles can be reagents for measuring the level of SPARC mRNA in extracellular vesicles known or under research in the art, including but not limited to PCR-based methods such as various quantitative PCRs, probe hybridization-based methods such as FISH, northern blot, etc. These methods and reagents available therein are well known to those skilled in the art or can be determined by referring to known textbooks or literature.
[0023] The reagents and methods in this application can be used for human samples, and primate or other mammal samples can also be used after appropriate adjustments. The sample is preferably serum, and plasma, urine, saliva, semen, milk, water, sweat, cerebrospinal fluid and other samples containing extracellular vesicles can also be used. The corresponding extracellular vesicle extraction method is well known to those skilled in the art or can be determined by referring to known textbooks or literature.
[0024] In this application, SPARC, Secreted protein acidic and rich in cysteine, BM-40 and osteonectin can be used interchangeably to express the same meaning; their specific amino acid sequences may differ depending on sample sources, mutations, etc., but are all within the scope of protection of this application.
[0025] Hypertension in this application includes but is not limited to various primary and secondary hypertension, such as hypertension caused by genetics, mental factors, lifestyle, drugs, and other diseases, preferably primary hypertension. The diagnosis of hypertension may vary according to different diagnostic criteria, and is not limited to the 2018 version of the ESC and ESH standards used in the examples of this application.
[0026] Hypertension-related diseases in this application refer to diseases that are associated with hypertension in existing knowledge or research, including but not limited to obesity, cerebral hemorrhage, headache, cardiovascular diseases such as coronary heart disease, angina pectoris, atrial fibrillation, arteriosclerosis, retinal hemorrhage and lower limb arteriosclerosis.
[0027] The method of the present application can be used for diagnostic or non-diagnostic purposes. Non-diagnostic uses include analysis and selection of samples in clinical experiments, scientific research purposes, macro-population health status testing, etc.
[0028] A system for executing the detection method of the present application can be constructed by those skilled in the art based on conventional knowledge in the art, and includes components including but not limited to instruments used in each step, such as a centrifuge, a fluorescence detection instrument, a PCR instrument, an instrument for data analysis, etc.
[0029] Beneficial effects:
[0030] 1. The invented biomarkers are used to improve the sensitivity and specificity of diagnosing or assisting in the diagnosis of essential hypertension, and to carry out further diagnosis or treatment of individual essential hypertension.
[0031] 2. The biomarkers of the present invention are used to detect the effectiveness of disease treatment. The biomarkers can assist in detecting the effectiveness of treatment regimens such as angiotensin converting enzyme inhibition and angiotensin II receptor inhibitors in treating hypertension and hypertension-related diseases.
[0032] 3. The biomarker of the present invention, serum extracellular vesicle SPARC, is used to detect the disease progression of hypertension-related diseases.
[0033] 4. The biomarker of the present invention, serum extracellular vesicle SPARC, provides disease classification, screening, monitoring or a basis for treatment plans for individuals suffering from or suspected of having hypertension.
[0034] 5. The goal of the biomarkers of the present invention is to determine the risk of hypertension and its related diseases. This invention provides the use of serum extracellular vesicle SPARC content to identify whether a patient is at risk of suffering from hypertension and its related diseases; at the same time, this invention also establishes a systematic procedure for testing patients. For example, subjects with higher levels of serum extracellular vesicle SPARC (for example, SPARC in serum extracellular vesicles extracted from 1 mL of serum is higher than 248 ng) will need to undergo clinical hypertension testing or blood tests more frequently. The specific implementation of this procedure will vary depending on the age, gender, health level, weight, and especially the extracellular vesicle SPARC protein index of the individual subject. In some embodiments, the recommended SPARC detection procedure is not necessarily based on the high and low values involved in this invention. These detection values can be divided into different levels according to the source of the biological sample and other detection methods.
[0035] 6. For clinical diagnosis of hypertension, serum extracellular vesicle SPARC protein content combined with clinical blood pressure detection can more accurately determine the risk and degree of hypertension. That is, the present invention provides methods, kits, devices and systems for associating the results of testing hypertension markers with systolic and diastolic blood pressure. Systolic and diastolic blood pressure are currently the key indicators for judging hypertension.
[0036] 7. The higher the consistency of serum extracellular vesicle SPARC protein changes, the greater the risk of hypertension. The sensitivity and specificity of the test can be further determined by combining the results of physical signs, blood pressure and related clinical conditions (e.g., stroke, aging, coronary artery disease, atherosclerosis, lipid indicators and coronary heart disease) with the expression level based on serum extracellular vesicle detection. When this information indicates an increased possibility of hypertension, a 1mL patient blood sample can indicate that the patient may have a history of hypertension that he or she is not aware of or has newly discovered hypertension or is at risk of hypertension.
[0037] 8. Combining the results increases the accuracy of further diagnosis of hypertension. That is, combining blood pressure monitoring with biomarkers can more accurately detect the patient's pathological state and distinguish hypertension. For example, the increase of serum extracellular vesicle SPARC in non-hypertensive people and hypertensive people indicates a hypertensive state, but if it is in obese people and hypertensive people, the specificity of hypertension diagnosis can be increased. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 This is the basic experimental flow chart for this application;
[0039] Figure 2 Flow chart of the method for extracting extracellular vesicles from serum;
[0040] Figure 3 This is an identification diagram of a typical serum extracellular vesicle;
[0041] Figure 4 This is the ROC curve analysis diagram for serum extracellular vesicle SPARC in diagnosing hypertension. DETAILED DESCRIPTION
[0042] Example 1 Source of experimental samples and basic experimental methods
[0043] Serum source and collection:
[0044] All research subjects gave written informed consent as appropriate before enrollment. The protocol was approved by the Medical Ethics Committee of Beijing Anzhen Hospital (No. 20175) and complied with the Declaration of Helsinki. China Clinical Trial Registration Number ChiCTR-ROC-17011027. All research subjects came from the Department of Hypertension and the Department of Otolaryngology and Head and Neck Surgery of Beijing Anzhen Hospital. In order to reduce the confounding of samples and reduce the interference of other diseases on experimental data, this study strictly excluded secondary hypertension, pregnancy, tumors, mental and neurological disorders and other diseases. In addition, we collected data on the characteristics of the research subjects, including clinical / biochemical factors. Demographic data, risk factors and laboratory parameters were obtained from clinical records. The specific requirements are as follows:
[0045] 1.1 Requirements for inclusion of patients with essential hypertension The diagnostic criteria for essential hypertension (EH) were based on the 2018 hypertension management guidelines jointly issued by the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), which stated that the diagnostic criteria for hypertension were: systolic blood pressure (SBP) ≥ 140 mmHg and / or diastolic blood pressure (DBP) ≥ 90 mmHg without the use of antihypertensive drugs. After excluding secondary hypertension, myocardial infarction, coronary heart disease, stroke, kidney disease, drug addiction or other serious diseases, essential hypertension was finally determined. All healthy controls had no family history of essential hypertension. All procedures were performed in accordance with the protocol approved by the local hospital ethics review committee, and informed consent was obtained from all participants. There were 79 people in the hypertension group.
[0046] The control group required that the research subjects had no tumors and no hypertension, and there were 42 people in the non-hypertensive group.
[0047] Body Measurements:
[0048] Anthropometric measurements and blood draws were performed on the same day. Height and weight were measured with participants wearing light indoor clothing and barefoot, using a calibrated portable electronic scale and a portable inflexible height measuring rod. Blood pressure was measured after 5 minutes of rest in a seated position, at least three times on the right upper arm, and the average was used in the analysis. Body mass index (BMI) was calculated using the standard BMI formula: body mass (kg) divided by the square of height (m2). Nonsmokers were defined as patients who had never smoked or had stopped smoking ≥1 year before joining the study. All remaining subjects were classified as smokers. Drinkers were defined as daily alcohol intake ≥ three times per week. Participants were asked not to eat after 21:00 the previous evening. Overnight fasting blood samples were drawn from each participant using serum collection tubes. They were then centrifuged at 3,000 g for 10 minutes at 4°C. Subsequently, serum samples were stored in a −80°C freezer within 2 hours of collection. Samples were thawed at 4°C before assays. Glucose, high-sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride (TG) levels were measured in the laboratory of Beijing Anzhen Hospital using standard enzymatic methods (Biotecnica Instruments, Italy).
[0049] Table 1. Basic clinical information of patients.
[0050]
[0051]
[0052] Serum Extracellular Vesicle Extraction:
[0053] EVs were isolated according to the International Extracellular Vesicles Association's protocol using a step-wise centrifugation method (e.g. Figure 2 , as shown in the figure. Take 2 mL of morning blood serum, dilute it with an equal amount of PBS, wash the cells first, centrifuge at 4,000 × g for 30 minutes at 4°C, remove the cell debris and aggregates and keep the supernatant; centrifuge at 110,000 × g, 4°C in a Beckman (USA) ultracentrifuge for 70 minutes, then resuspend the EVs particles in 1.5 mL of sterile PBS (after filtering with a 0.22 μm filter), centrifuge again at 110,000 × g, 4°C for 70 minutes, and the precipitate is the purified serum extracellular vesicles. Then, discard the supernatant and freeze the serum extracellular vesicles in a -80°C refrigerator.
[0054] Verification of extracellular vesicles under electron microscopy:
[0055] After ultracentrifugation, the size and morphology of serum extracellular vesicles were determined. The extracellular vesicles were first stained using a negative staining technique, and the size and shape of the extracellular vesicles were captured by transmission electron microscopy at an accelerating voltage of 80 kV (Hitachi H-7650, Tokyo, Japan).
[0056] Measurement of serum extracellular vesicle SPARC levels:
[0057] magnetic The assay is a magnetic bead-based antibody microarray, built on the principle of sandwich immunoassay, which can be used to assess the levels of biomarkers in a single sample. According to the instructions, all serum samples were tested at a dilution of 1:2 with sterile PBS. 50 μl / well of standard was added to a 96-well plate, and the diluted microparticle mixture was added to each well; then, the plate was placed on a shaker and incubated at 800 rpm at room temperature for 2 hours; the liquid in each well was washed out with 100 μl / well of wash buffer for a total of three times; 50 μl of diluted biotin-antibody mixture was added to each well and covered, and incubated on a shaker at room temperature for 1 hour at 800 rpm; the liquid in each well was washed out with 100 μl / well of wash buffer for a total of three times; then, 50 μl of diluted The cells were then incubated on a shaker at 800 rpm for 30 min at room temperature with a streptavidin-erythrin conjugate and covered; the liquid in each well was washed three times with 100 μL / well of wash buffer; 100 μL of wash buffer was added to each well and washed and incubated on a shaker at 800 rpm for 2 min at room temperature; finally, serum extracellular vesicle SPARC levels were measured and analyzed using a Luminex-based multiplex detection plate (R&D Systems, Minneapolis, MN, USA) using a Bio-Plex analyzer (Bio-Rad Laboratories, Inc., Hercules, CA), with intra- and inter-assay coefficients of variation less than 5% and 10%, respectively.
[0058] Statistical analysis:
[0059] Statistical analyses were performed by SPSS, version 25.0 (IBM Corp., Armonk, NY). Continuous variables were expressed as mean ± SD or median (interquartile range), and categorical variables were expressed as numbers (percentages). In these analyses, variables with skewed distributions were log-normal transformed. Baseline characteristics between the two groups were compared using nonparametric Mann-Whitney U test, independent t test, or chi-square test. Simple and multivariate linear regression analyses were used to investigate the association between serum extracellular vesicle SPARC levels and other parameter values. The association between serum extracellular vesicle SPARC levels and hypertension was determined by multivariate logistic regression analysis. Multivariate-adjusted ORs were presented with 95% confidence intervals (CIs). The differential expression of serum extracellular vesicle SPARC was presented as violin plots, generated in Graphpad prism version 9.0.0. P < 0.05 (two-tailed) indicated statistical significance.
[0060] Example 2 Experimental Results and Analysis
[0061] Isolation and purification of extracellular vesicles from serum:
[0062] The extracellular vesicles in the serum of the hypertension group were purified by ultracentrifugation and filtration. The size and shape of the extracellular vesicles in human serum were observed by electron microscopy and found that the extracellular vesicles were round and most of them were less than 100nm in diameter ( Figure 3 ).
[0063] Serum extracellular vesicle SPARC levels and other clinical characteristics of the study subjects:
[0064] The serum extracellular vesicle SPARC levels of the total population tested were binned into two quartiles, with the population divided into greater than 248 ng / mL (N = 60) and less than 248 ng / mL (N = 61). We found that age, BMI, systolic blood pressure, diastolic blood pressure, and the presence or absence of hypertension were significantly different between the groups (Table 1).
[0065] Correlation of serum extracellular vesicle SPARC levels with anthropometric, biochemical, and clinical parameters:
[0066] We used Spearman's rho correlation analysis to investigate the correlation between serum extracellular vesicle SPARC levels and clinical and biochemical variables in the overall study subjects. The results showed that when all the subjects were analyzed together, serum extracellular vesicle SPARC levels were correlated with age (r = -0.474, p < 0.001), blood glucose (r = -0.207, p = 0.023), high-sensitivity C-reactive protein (r = -0.179, p = 0.049), BMI (r = 0.239, p = 0.008) and diastolic blood pressure (r = 0.189, p = 0.038). In addition, in the hypertensive group, serum extracellular vesicle SPARC levels were correlated with age (r = -0.479, p < 0.001), blood glucose (r = -0.273, p = 0.015), BMI (r = 0.307, p = 0.006) and diastolic blood pressure (r = 0.225, p = 0.036). However, in the non-hypertensive group, extracellular vesicle SPARC levels were only correlated with age (r = -0.390, p = 0.011) (Table 2). We further used Spearman's rho correlation analysis to investigate the correlation between serum extracellular vesicle SPARC levels and clinical and biochemical variables in hypertensive subjects. The results showed that serum extracellular vesicle SPARC levels in treated hypertensive patients were correlated with age (r = -0.573, p < 0.001), blood glucose (r = -0.285, p = 0.049) and BMI (r = 0.357, p = 0.013). In addition, serum extracellular vesicle SPARC levels were only correlated with age (r = -0.479, p < 0.001) in newly diagnosed hypertensive patients (Table 3). These results showed that SPARC was mainly associated with increased diastolic blood pressure in hypertensive patients, suggesting that SPARC, as an extracellular matrix component, may mainly affect vascular diastolic blood pressure.
[0067] Table 2. Correlation analysis of variables related to serum extracellular vesicle SPARC among the study subjects.
[0068]
[0069]
[0070] Table 3. Correlation analysis of variables related to serum extracellular vesicle SPARC in hypertensive subjects.
[0071]
[0072]
[0073] Multivariate logistic regression of serum extracellular vesicle SPARC levels and the presence or absence of hypertension in the study subjects:
[0074] We constructed a multivariate logistic regression model including covariates to further evaluate the association between serum extracellular vesicle SPARC and hypertension. Univariate analysis showed (Table 4) that serum extracellular vesicle SPARC levels were associated with hypertension (OR (95% CI): 1.088 (1.039-1.138), P = 0.001). After adjusting for conventional hypertension risk factors, including age, sex, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein, increased serum extracellular vesicle SPARC levels showed a higher OR value (OR (95% CI): 1.105 (1.046-1.200), P = 0.001). Then we divided all the subjects into obese group and non-obese group (Table 4). Univariate analysis showed that in the non-obese group, serum extracellular vesicle SPARC level was associated with hypertension (OR (95% CI): 1.075 (1.012-1.142), P = 0.019). After adjusting for age, gender, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglyceride, and high-sensitivity C-reactive protein, the OR value increased (OR (95% CI): 1.091 (1.002-1. 188), P = 0.046); in the obese group, univariate analysis showed that serum extracellular vesicle SPARC levels were associated with hypertension (OR (95% CI): 1.114 (1.041-1.191), P = 0.002). After adjusting for age, gender, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein, the OR value was found to be increased (OR (95% CI): 1.186 (1.064-1.322), P = 0.002). Afterwards, we divided all the subjects into the young group and the non-elderly group (Table 5). In the young group, univariate analysis showed that serum extracellular vesicle SPARC levels were associated with hypertension (OR (95% CI): 1.056 (1.005-1.110), P = 0.030). After adjusting for age, sex, body mass index, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein, the OR value increased (OR (95% CI): 1.112 (1.033-1. 128), P=0.021); in the elderly group, univariate analysis showed that serum extracellular vesicle SPARC levels were associated with hypertension (OR (95% CI): 1.199 (1.081-1.330), P=0.001). After adjusting for age, sex, body mass index, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein, the OR value was found to be increased (OR (95% CI): 1.361 (1.145-1.698), P<0.001).All subjects were divided into high hs-CRP group and low hs-CRP group (Table 6). Univariate analysis showed that serum extracellular vesicle SPARC level was associated with hypertension in the low hs-CRP group (OR (95% CI): 1.099 (1.025-1.179), P = 0.008), and after adjusting for age, sex, BMI, smoking, drinking, HDL-cholesterol, LDL-cholesterol, and triglycerides, the OR value was found to be increased (OR (95% CI): 1.112 (1.033-1.198), P = 0.005); univariate analysis showed that serum extracellular vesicle SPARC level was associated with hypertension in the high hs-CRP group (OR (95% CI): 1.087 (1.013-1.153), P = 0.018), and after adjusting for age, sex, BMI, smoking, drinking, HDL-cholesterol, LDL-cholesterol, and triglycerides. It was later found that the OR value increased (OR (95% CI): 1.147 (1.045-1.198), P = 0.004). Based on the above statistical analysis, the increase in serum extracellular vesicle SPARC levels is an independent risk factor for hypertension.
[0075] Table 4. Relationship between serum extracellular vesicle SPARC and obesity and hypertension in all study subjects.
[0076]
[0077] Model 1 included: age, sex, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein. Obesity: BMI>30kg / m 2 .
[0078] Table 5. Relationship between serum extracellular vesicle SPARC and age and hypertension in all study subjects.
[0079]
[0080]
[0081] Model 1: age, sex, body mass index, smoking, drinking, high-density lipoprotein, low-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein.
[0082] Aged > 60 years.
[0083] Table 6. Relationship between serum extracellular vesicle SPARC and low or high hs-CRP and hypertension in all study subjects.
[0084]
[0085] Model 1: age, sex, BMI, smoking, drinking, HDL-cholesterol, LDL-cholesterol, triglycerides.
[0086] ROC curve evaluates the efficacy of serum extracellular vesicle SPARC in diagnosing hypertension:
[0087] ROC curve Figure 4 As shown in the figure, the area under the ROC curve of serum extracellular vesicle SPARC is 0.854 (95% confidence interval: 0.782-0.927, p<0.001), and the point with the largest Youden index is found as the critical value (Youden index = the sum of sensitivity and specificity minus 1). When the serum extracellular vesicle SPARC concentration is higher than 19.428 ng / mL, the sensitivity and specificity of diagnosing hypertension are 95.06% and 62.50%, respectively; the positive predictive value is 83.70%, and the negative predictive value is 86.21%. Therefore, the extremely high sensitivity of this factor indicates a low missed diagnosis rate, but the relatively low specificity indicates that there are a small number of false positive results, which provides great help for the diagnosis of essential hypertension. SPARC in serum extracellular vesicles has good clinical application prospects as a hypertension biomarker.
[0088] Table 7. ROC curve of serum extracellular vesicle SPARC for predicting hypertension: sensitivity, specificity, positive predictive value, and negative predictive value
[0089]
[0090] Obviously, the above embodiments of the present invention are only examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. However, these obvious changes or modifications derived from the spirit of the present invention are still within the scope of protection of the present invention.
[0091] References:
[0092] 1Zhou M, Wang H, Zeng Xet al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burdenof Disease Study 2017Lancet 394(10204),1145-1158(2019).
[0093] 2Wang Z,Chen Z,Zhang Let al.Status of Hypertension in China:ResultsFrom the China Hypertension Survey,2012-2015Circulation 137(22),2344-2356(2018).
[0094] 3Laragh JH Lewis K.Dahl Memorial Lecture.The renin system and fourlines fo hypertension research.Nephron heterogeneity,the calcium connection,the prorenin vasodilator limb,and plasma renin and heart attack Hypertension20(3),267-279(1992).
[0095] 4Rosendorff C The renin-angiotensin system and vascular hypertrophy JAm Coll Cardiol 28(4),803-812(1996).
[0096] 5Brandes RP Endothelial dysfunction and hypertension Hypertension 64(5),924-928(2014).
[0097] 6Camilletti A,Moretti N,Giacchetti Get al.Decreased nitric oxidelevels and increased calcium content in platelets of hypertensive patients AmJ Hypertens 14(4Pt 1),382-386(2001);Ferroni P,Martini F,D'Alessandro Retal.In vivo platelet activation is responsible for enhanced vascularendothelial growth factor levels in hypertensive patients Clin Chim Acta 388(1-2),33-37(2008).
[0098] 7 Dharmashankar K,Widlansky ME Vascular endothelial function andhypertension:insights and directions Curr Hypertens Rep 12(6),448-455(2010).
[0099] 8 Kim DH,Kim C,Ding EL,Townsend MK,Lipsitz LA Adiponectin levels andthe risk of hypertension:a systematic review and meta-analysis Hypertension62(1),27-32(2013).
[0100] 9 Di Vizio D,Kim J,Hager MHet al.Oncosome formation in prostatecancer:association with a region of frequent chromosomal deletion inmetastatic disease Cancer Res 69(13),5601-5609(2009).
[0101] 10 Keller S,Ridinger J,Rupp AK,Janssen JWG,Altevogt P Body fluidderived exosomes as a novel template for clinical diagnostics Journal ofTranslational Medicine 9(2011).
[0102] 11 Simons M,Raposo G Exosomes--vesicular carriers for intercellularcommunication Curr Opin Cell Biol 21(4),575-581(2009).
[0103] 12 Brekken RA,Sage EH SPARC,a matricellular protein:at the crossroadsof cell-matrix Matrix Biol 19(7),569-580(2000).
[0104] 13 Lane TF,Sage EH The biology of SPARC,a protein that modulatescell-matrix interactions FASEB J 8(2),163-173(1994).
[0105] 14 Francki A,Bradshaw AD,Bassuk JA,Howe CC,Couser WG,Sage EH SPARCregulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells J Biol Chem 274(45),32145-32152(1999).
[0106] 15 Taneda S,Pippin JW,Sage EHet al.Amelioration of DiabeticNephropathy in SPARC-Null Mice Journal of the American Society of Nephrology14(4),968-980(2003).
[0107] 16 Kanauchi M,Nishioka M,Dohi K Secreted protein acidic and rich incysteine (SPARC)in patients with diabetic nephropathy and tubulointerstitialinjury Diabetologia 43(8),1076-1077(2000).
[0108] 17 Kotani K,Yamada T,Taniguchi N The association between circulatingsecreted protein acidic and rich in cysteine(SPARC)and glycosylatedhaemoglobin(HbA(1c))during lifestyle-modified weight reduction interventionin obese male subjects J Int Med Res 39(2),528-532(2011).
[0109] 18 Kos K,Wong S,Tan Bet al.Regulation of the fibrosis andangiogenesis promoter SPARC / osteonectin in human adipose tissue by weightchange,leptin,insulin,and glucose Diabetes 58(8),1780-1788(2009).
[0110] 19 Socha MJ,Manhiani M,Said N,Imig JD,Motamed K Secreted proteinacidic and rich in cysteine deficiency ameliorates renal inflammation andfibrosis in angiotensin hypertension Am J Pathol 171(4),1104-1112(2007).
[0111] 20 Bradshaw AD,Baicu CF,Rentz TJet al.Pressure overload-inducedalterations in fibrillar collagen content and myocardial diastolic function:role of secreted protein acidic and rich in cysteine(SPARC)in post-syntheticprocollagen processing Circulation 119(2),269-280(2009).
Claims
1. Use of a reagent for detecting the SPARC content in extracellular vesicles in the preparation of a kit for diagnosing primary hypertension; the extracellular vesicles are extracellular vesicles in serum; the reagent for detecting the SPARC content in extracellular vesicles includes an extracellular vesicle extraction reagent and a reagent for measuring the SPARC content in extracellular vesicles.
2. The use according to claim 1, wherein the reagent for measuring the SPARC content in extracellular vesicles is Assay reagents, ELISA reagents, mass spectrometry reagents, flow cytometry reagents or western blot reagents.
3. The use according to claim 2, wherein the reagent for measuring the SPARC content in extracellular vesicles is Detection reagents.
